Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN (ACR Convergence 2025) - Sep 15, 2025 - Abstract #0667; Pres time: Oct 26, 2025; 10:30 AM - 12:30 PM; Location: Hall F1; In Person; "Notably, since the previous guidelines update in 2012, the FDA has approved belimumab and voclosporin for the treatment of LN. 1,017 moderate-to-severe (M/S) adult SLE patient records were collected in collaboration with 176 US rheumatologists via an online survey platform from January through March 2025...These patients also had to exhibit active, new-onset, or flaring renal disease, defined as an LN diagnosis within the past five years, a flare within the past six months, or active renal involvement at their most recent rheumatology visit. ACR strongly recommends that patients with Class III, IV, or V LN be treated with hydroxychloroquine (HCQ), unless contraindicated...Our analysis shows that 69.3% of these patients are on RAAS-I therapy, most commonly ACE inhibitors such as lisinopril and enalapril...Only 51.5% of patients who are on oral steroid dosages exceeding 5mg per day are currently on a regimen consisting of belimumab or a calcineurin inhibitor (CNI),..."
Retrospective data • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology
|
|
Sawyer May1; Lynn Price1; Ryan Rex2
|